Feasibility and diagnostic yield of a photoplethysmography-based arrhythmia screening and integrated management pathway in a COPD outpatient clinic
- PMID: 41158482
- PMCID: PMC12557434
- DOI: 10.1183/23120541.01192-2024
Feasibility and diagnostic yield of a photoplethysmography-based arrhythmia screening and integrated management pathway in a COPD outpatient clinic
Abstract
Background and aims: Guidelines recommend opportunistic atrial fibrillation (AF) screening in high-risk populations, including COPD patients. This cohort study aimed to evaluate the feasibility and yield of a photoplethysmography (PPG)-based mHealth pathway for AF detection in a COPD outpatient clinic.
Methods: COPD patients at Maastricht University Medical Centre+ were invited to participate in a 14-day PPG-based AF screening embedded within the COPD care pathway using their smartphone.
Results: Out of 155 invited moderate-to-severe COPD patients, 99 (mean age 66±9 years, 54% female) participated in the AF screening. Adherence (101% (82-123%)) and patient satisfaction (System Usability Score 80.0 (IQR 55.0-92.5)) were high. The PPG-based pathway detected 8 of 99 (8.1%) AF cases (6 new and 2 known AF). Additional cardiac work-up of the six new cases revealed ECG-confirmed AF in two (2.0%) patients and frequent premature beats in three patients. PPG analysis showed additional arrhythmias in 95 of 99 patients (isolated premature beats) and 31 of 99 patients (frequent premature beats), of which 8 (8.0%) patients necessitated additional cardiac analysis. The overall diagnostic yield of PPG-based AF screening was thus 8%, yield of ECG-confirmed new AF was 2% and in 10% of the patients, additional arrhythmias were detected. Of the 99 patients, 12 of 99 (12%) patients needed referral to cardiac work-up.
Conclusion: 14-day opportunistic PPG-based, mHealth-supported AF screening is feasible in COPD outpatient care and results in the detection of new AF cases and premature beats. This novel digital approach offers a practical guidance for implementing recommended AF screening and management in COPD patients.
Copyright ©The authors 2025.
Conflict of interest statement
Conflict of interest: F.M.E. Franssen reports grants and personal fees from AstraZeneca, Chiesi and GlaxoSmithKline, personal fees from Pieris, and grants and personal fees from Sanofi, outside the submitted work. S.O. Simons reports grants from AstraZeneca, Chiesi, and Roche, consulting fees from AstraZeneca and Chiesi, payment for lectures and presentations from AstraZeneca and Chiesi, and support for attending meeting from AstraZeneca and Chiesi, all outside the submitted work and paid to his institution. The other authors have nothing to disclose.
Figures
References
LinkOut - more resources
Full Text Sources